Investor Relations
India's Most Differentiated Orthopaedic Implant Platform
FlexiScrew — India's first bioabsorbable bone screw co-developed with IIT Delhi and AIIMS New Delhi under ICMR mPragati — paired with a revenue-generating titanium trauma portfolio. Seed round: INR 65–85 lakhs.
The Opportunity
A large, import-dependent market at the inflection point
India's orthopaedic implant market is overwhelmingly import-dependent. With no domestic bioabsorbable screw manufacturer, every FlexiScrew sold is direct import substitution — aligned with PLI scheme incentives and government procurement preferences. The titanium portfolio addresses the immediate high-volume trauma fixation need while FlexiScrew clears regulatory approval.
PLACEHOLDER — update with actual market size figure from research
PLACEHOLDER — update with actual CAGR from industry report
PLACEHOLDER — proportion of implants currently imported
PLACEHOLDER — annual surgically relevant fracture cases in India
Metallic screws used today require a second surgery for removal — adding cost, anaesthesia risk, and operative time. Import dependency means high landed cost, long lead times, and no domestic innovation pipeline.
FlexiScrew's bioresorbable outer shell degrades naturally — eliminating the second surgery. Made in India, validated by IIT Delhi and AIIMS, priced to compete with imports, and aligned with CDSCO Class C pathway.
What We Have Built
Three defensible assets built before this round
FlexiScrew — India's First Bioabsorbable Screw
TRL 5A bi-component bioresorbable bone screw co-developed under the ICMR mPragati programme at IIT Delhi with AIIMS New Delhi. Outer shell resorbs naturally — eliminating revision surgery. Currently at TRL 5 (small animal complete, large animal ongoing). CDSCO Class C classification.
Titanium Trauma Portfolio — Phase 1 Launched
Revenue Live7 anatomically contoured Ti-6Al-4V ELI (ASTM F136) locking plate systems and 8 hex-drive screw variants. Revenue-generating product line providing cash-flow while FlexiScrew progresses through regulatory pathway. Gamma-sterilized via BRIT.
Institutional Research Backbone
IIT Delhi + AIIMSFormal technology transfer relationship with IIT Delhi via FITT (Foundation for Innovation and Technology Transfer). AIIMS New Delhi clinical co-development partnership. Backed by ICMR mPragati government funding — de-risks the R&D stage significantly.
Investment Thesis
Six reasons Anatomica wins this market
First-Mover in India
No domestic competitor has a bioabsorbable bone screw with institutional research validation at this stage. Import substitution directly serves the Government of India's 'Make in India' healthcare mandate.
IIT Delhi IP & ICMR Backing
Technology licensed from IIT Delhi via FITT. ICMR mPragati funding provides non-dilutive R&D capital. The institutional umbrella accelerates regulatory credibility with CDSCO.
Dual Revenue Model
Ti-6Al-4V titanium trauma portfolio generates near-term revenue while FlexiScrew completes regulatory pathway. Investors are not waiting on a single product — cash flow is live.
CDSCO Class C Pathway
Bioabsorbable screws classified as Class C — a defined, navigable pathway with precedent in India. Regulatory risk is well-understood and bounded. Large animal completion is the key remaining gate.
Surgeon-Designed Products
AIIMS surgeons co-developed both product lines. Clinical adoption risk is lower when the product is developed by the same fraternity that will implant it.
Scalable Manufacturing
ISO 13485-certified manufacturing processes with BRIT for gamma sterilization. Designed for scale-up without facility capex — contractable to existing certified manufacturers in India.
The Ask
Seed round — INR 65–85 lakhs
This round funds the completion of FlexiScrew large animal studies, CDSCO Class C submission, and 18 months of runway. The titanium portfolio continues to generate revenue in parallel. Valuation and instrument details available under NDA.
Large animal study completion, CDSCO Class C pre-submission dossier, biocompatibility testing, and GLP-compliant pre-clinical data package.
FlexiScrew pilot batch production tooling, BRIT sterilization validation lots, and QMS documentation for Class C submission.
Surgeon outreach, KOL engagement, clinical training events, and expansion of titanium portfolio into tier-2 hospital networks.
Clinical Affairs Manager hire, Regulatory Affairs consultant (CDSCO specialist), and working capital buffer for first 18 months.
Traction
Milestones achieved before this raise
ICMR mPragati Grant
IIT Delhi awarded ICMR mPragati funding for FlexiScrew development
Anatomica Founded
Company incorporated; IIT Delhi technology transfer agreement via FITT executed
TRL 5 Achieved
FlexiScrew small animal studies completed successfully. CDSCO classification confirmed as Class C
Phase 1 Titanium Launch
7-plate Ti-6Al-4V ELI locking system + 8-screw variant portfolio launched commercially
Large Animal Underway
Porcine/ovine biomechanical validation at AIIMS; CDSCO pre-submission meeting targeted
CDSCO Submission
CurrentClass C application filing; FlexiScrew Phase 1 commercial launch target [PLACEHOLDER — confirm timeline]
Investor Enquiry
Interested in learning more?
We share our investor deck, financial model, and due diligence materials under NDA. Reach out to schedule a founder call or request the pitch deck.
Investor Deck
Available under NDA — request via email [PLACEHOLDER — add pitch deck PDF link]
Schedule a Founder Call
30-minute intro call with the founding team. Available for angels, family offices, and institutional early-stage funds.
Email for Investor DeckAlternatively, connect via the contact page.
This page contains forward-looking statements and projections. Market size figures marked [PLACEHOLDER] require update with verified research data before publication. Financial projections and timelines are indicative and subject to change. This does not constitute a public offering of securities. All investment discussions are conducted under NDA and in compliance with applicable SEBI regulations.